Gri Bio, INC. (GRI) — DEF 14A Filings

All DEF 14A filings from Gri Bio, INC.. Browse 6 Proxy Statement reports with AI-powered summaries and risk analysis.

DEF 14A Filings (6)

GRI Bio Seeks Shareholder Nod for Reverse Stock Split — Dec 29, 2025 Risk: medium
GRI Bio, Inc. (GRI) is seeking stockholder approval for a reverse stock split of its common stock, with a proposed ratio ranging from one-for-two to one-for-30.
GRI Bio Schedules Virtual 2025 Annual Meeting, Board Backs All Proposals — Jul 11, 2025 Risk: low
GRI Bio, Inc. has filed a Definitive Proxy Statement (DEF 14A) on July 11, 2025, for its 2025 Annual Meeting of Stockholders, scheduled for August 13, 2025, at
GRI Bio Files Definitive Proxy Statement — Jan 17, 2025 Risk: low
GRI Bio, Inc. filed a definitive proxy statement (DEF 14A) on January 17, 2025, for its fiscal year ending December 31, 2024. The company, formerly known as Val
GRI BIO, Inc. Files Definitive Proxy Statement — Aug 2, 2024 Risk: low
GRI BIO, Inc. filed its definitive proxy statement on August 2, 2024, for its annual meeting of stockholders. The company, formerly known as Vallon Pharmaceutic
GRI BIO, Inc. Announces Special Stockholder Meeting on June 7, 2024 — May 9, 2024 Risk: low
GRI BIO, Inc. (GRI) filed a Proxy Statement (DEF 14A) with the SEC on May 9, 2024. GRI Bio, Inc. will hold a special meeting of stockholders on June 7, 2024, at
GRI Bio, Inc. Announces Special Meeting of Stockholders on January 19, 2024 — Jan 2, 2024 Risk:
GRI BIO, Inc. (GRI) filed a Proxy Statement (DEF 14A) with the SEC on January 2, 2024. GRI Bio, Inc. will hold a special meeting of stockholders on January 19,

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX